Why did the CSL share price sink 10% in June?

CSL shares were out of form in June. But why were investors hitting the sell button?

| More on:
A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • CSL shares were sold off in June
  • This was driven by the release of a disappointing market update
  • CSL revealed FY 2024 profit guidance well short of what the market was expecting

The CSL Limited (ASX: CSL) share price had a tough time in June.

During the month, the biotherapeutics giant's shares lost approximately 10% of their value.

As a comparison, the S&P/ASX 200 Index (ASX: XJO) rose 1.6% over the same period.

Why did the CSL share price tumble in June?

Investors were selling down the CSL share price in June after the company released a disappointing market update.

That update revealed that management now expects a foreign currency headwind of US$230 million to US$250 million in FY 2023. This is up from its previous estimate of US$$175 million for the 12 months.

And while its constant currency profit guidance for FY 2023 was unchanged and is actually now skewed to the top end of its guidance range, comments about its expectations for the following year overshadowed this.

Management advised that it is projecting profit growth of ~13% to 18% to the range of ~US$2.9 billion and US$3 billion in constant currency in FY 2024.

This was well short of expectations, with the market previously believing that favourable plasma collection tailwinds were going to support margin expansion and drive even stronger growth.

Commenting on the update, analysts at Citi said:

CSL increased the FX headwind guidance for FY23 and provided FY24 NPATA guidance which was ~12% below VA consensus.

The trading update was about resetting the market's expectations for the recovery of gross margins in the Behring division, as both donor fees and labour cost inflation remain higher than anticipated. CSL now expects Behring GM to recover to pre-covid levels in 3-5 years (FY26-28) – the market was expecting a sharper recovery by FY26. We now expect FY27.

Nevertheless, the broker believes that this selloff has created a buying opportunity for investors. It retained its buy rating with a trimmed price target of $340.00. It added:

We cut our above market FY23-25e NPATA per share (Core EPS) by -4%/-17%/-17% and cut our TP to $340 (from $350). Our TP implies CSL should trade on an FY26 PE of ~27x, in line with the 10-year average. Maintain Buy. The next catalyst is the release of the argenx trial data expected in July (argenx CIDP trial data expected in July).

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »